Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Vesigen Therapeutics, Inc. logo — Delivering intracellular therapeutics with ARMMed microvesic...

Vesigen Therapeutics, Inc.

Delivering intracellular therapeutics with ARMMed microvesicles

Founded 2019 United States Cambridge, United States 19 employees Grant Total: $28.50M Biotechnology, Health and Wellness

General Information

Company Name Vesigen Therapeutics, Inc.
Founded Year 2019
Location United States Cambridge, United States
Employees 19
Industries Biotechnology, Health and Wellness
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with Vesigen Therapeutics, Inc.. To contact Vesigen Therapeutics, Inc., visit vesigen.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Vesigen Therapeutics, Inc. compare?

A PDF of Vesigen Therapeutics, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Vesigen Therapeutics, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Vesigen Therapeutics, Inc.

Vesigen Therapeutics is a biotechnology startup that aims to revolutionize therapeutic delivery to intracellular targets through its innovative ARMMed microvesicles technology. Founded in 2019 and headquartered in the United States, Vesigen is committed to addressing unmet medical needs by leveraging its patented ARMMs (ARRDC1 Mediated Microvesicles) technology. The company's groundbreaking technology allows for the delivery of a diverse range of payloads, including RNAs (mRNA, shRNA, ribozymes), proteins (signaling proteins, enzymes, antibody fragments), and editing complexes (Cas9/gRNA) directly into the cytoplasm of target cells. This capability expands the universe of druggable targets, offering promising prospects for the development of new therapies. Vesigen Therapeutics recently received a grant investment on 14 March 2023 from FARA, highlighting the industry's recognition of the potential of their technology. With its focus on intracellular therapeutic delivery, Vesigen is well-positioned to make significant contributions to the field of biotechnology and address critical unmet medical needs.

Business keywords: therapeutic products, intracellular delivery, RNA delivery, protein delivery, gene editing, druggable targets, innovative technology, medical innovation, biopharmaceuticals

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Grant Undisclosed 1
FARA
14 Mar 2023
Series A $28.50M 4
Alexandria Venture Investments Leaps by Bayer Linden Lake Ventures
Alexandria Venture Investments, Leaps by Bayer +2
22 Jul 2020

Vesigen Therapeutics, Inc. Alternatives & Competitors

View All Alternatives
Vesigen Therapeutics, Inc. vs
ReNAgade Therapeutics
ReNAgade Therapeutics United States

RNA Without Limits

Series A
24 employees
Biotechnology, Health and Wellness
Vesigen Therapeutics, Inc. vs
Edity Therapeutics
Edity Therapeutics Israel

Using human immune cells to deliver therapeutic proteins

Seed
22 employees
Biotechnology, Health and Wellness
Vesigen Therapeutics, Inc. vs
EnPlusOne Biosciences
EnPlusOne Biosciences United States

Harnessing the power and flexibility of enzymes to deliver RNA to the world

Seed
26 employees
Biotechnology, Health and Wellness
Also compare with: Vesigen Therapeutics, Inc. vs Feldan Therapeutics ǀ Feldan Thérapeutiques Feldan Therapeutics ǀ Feldan Thérapeutiques View all alternatives

FAQ About Vesigen Therapeutics, Inc.

Delivering intracellular therapeutics with ARMMed microvesicles
Vesigen Therapeutics, Inc. was founded in 2019.
Vesigen Therapeutics, Inc. is headquartered in Cambridge, United States.
Vesigen Therapeutics, Inc. operates in Biotechnology and Health and Wellness. Its work centres on therapeutic products, intracellular delivery, RNA delivery and protein delivery.
Vesigen Therapeutics, Inc. has approximately 19 employees.
Vesigen Therapeutics, Inc. has completed 2 funding rounds, raising a total of $28.50M. The latest funding stage is Grant.
Top alternatives and competitors to Vesigen Therapeutics, Inc. include ReNAgade Therapeutics, Edity Therapeutics , EnPlusOne Biosciences, BreezeBio, Kelonia Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Vesigen Therapeutics, Inc. and ReNAgade Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Vesigen Therapeutics, Inc., https://bouncewatch.com/company/vesigen-therapeutics, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout